MILESTONE: strona spółki
9.09.2020, 15:50
MMD The update on commercial roll-out and active trials of CompuFlo® Epidural System at premier hospitals
The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”) today provided a business update regarding the commercial roll-out of its CompuFlo® Epidural System and CathCheck™ technology.
With COVID-19 infections declining in certain regions, and a number of hospitals re-opening to outside vendors, the Board of Directors of the Company is advancing sales efforts around the CompuFlo® Epidural System and CathCheck™ technology. To support the hospitals in performing procedures during the pandemic, the Board of Directors of the Issuer decided to make the CompuFlo instrument more readily available to hospitals by lending the instrument to the hospital, in exchange for a commitment to purchase a minimum number of disposables. This offering is limited to the first hospitals that sign up for this program. At the same time, the Company is partnering with anesthesiologists, in order to approach the purchasing departments of the hospitals together. The Board of Directors of the Company believes that the current strategy allows the Issuer to streamline the Value Analysis Team (VAT) approval process, and thereby shorten the sales cycle. The response thus far has been encouraging, and the Company is increasing new trials in major hospitals over the coming weeks. The Board of Directors of the Company looks forward to finalizing agreements with several premier hospitals in the near future as the sales pipeline is more robust than ever.
With COVID-19 infections declining in certain regions, and a number of hospitals re-opening to outside vendors, the Board of Directors of the Company is advancing sales efforts around the CompuFlo® Epidural System and CathCheck™ technology. To support the hospitals in performing procedures during the pandemic, the Board of Directors of the Issuer decided to make the CompuFlo instrument more readily available to hospitals by lending the instrument to the hospital, in exchange for a commitment to purchase a minimum number of disposables. This offering is limited to the first hospitals that sign up for this program. At the same time, the Company is partnering with anesthesiologists, in order to approach the purchasing departments of the hospitals together. The Board of Directors of the Company believes that the current strategy allows the Issuer to streamline the Value Analysis Team (VAT) approval process, and thereby shorten the sales cycle. The response thus far has been encouraging, and the Company is increasing new trials in major hospitals over the coming weeks. The Board of Directors of the Company looks forward to finalizing agreements with several premier hospitals in the near future as the sales pipeline is more robust than ever.